Health and Healthcare

BioMarin : BMRN

All BioMarin Articles

171 Articles

Chris Lange | Jan 23, 2017 at 11:40 AM EST

Why Credit Suisse Sees 25% Upside at BioMarin

BioMarin Pharmaceutical may have missed out on the Trump rally, but it might not be too late to catch a…

Lee Jackson | Jan 19, 2017 at 8:40 AM EST

Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential

A recent research report from the biotech team at Baird offers their top picks for 2017. While hardly pounding the…

Lee Jackson | Dec 22, 2016 at 8:25 AM EST

RBC Likes Large Cap Biotech Leaders for 2017

In a new research report, the biotech team at RBC reveal their top picks for 2017, and while hardly pounding…

Jon C. Ogg | Nov 29, 2016 at 9:05 AM EST

Top Analyst Upgrades and Downgrades: AK Steel, Celgene, Darden, Delphi Automotive, Johnson & Johnson, US Steel and More

The top analyst upgrades, downgrades and initiations seen on Tuesday morning include AK Steel, Celgene, Darden Restaurants, Delphi Automotive, Johnson…

Jon C. Ogg | Nov 7, 2016 at 8:50 AM EST

Top Analyst Upgrades and Downgrades: GoPro, Randgold, Teva Pharma, Time Warner, Waste Management and More

The top analyst upgrades, downgrades and initiations seen on Monday morning include GoPro, Randgold Resources, Teva Pharmaceutical, Time Warner, Waste…

Jon C. Ogg | Nov 3, 2016 at 9:05 AM EDT

Top Analyst Upgrades and Downgrades: Brocade, Facebook, First Solar, Fitbit, ONEOK Partners, Sunrun and More

The top analyst upgrades, downgrades and initiations seen on Thursday morning include Brocade Communications Systems, Facebook, First Solar, Fitbit, ONEOK…

Chris Lange | Oct 23, 2016 at 10:35 AM EDT

Top Health Care Earnings Coming Next Week

Earnings season is now in full swing, and we have put together a preview of Bristol-Myers, AbbVie and some of…

Lee Jackson | Aug 31, 2016 at 8:20 AM EDT

3 Biotech Stocks Could Be the Next Big Takeover Targets

In a new research report, Baird notes two biotech companies in its research coverage universe that may be considered speculative…

Lee Jackson | Aug 4, 2016 at 10:40 AM EDT

Merrill Lynch Says the Time to Put Money Into Biotech Is Now

Though these four large cap biotech stocks are cheap relative to the S&P 500, history says they won’t stay that…

Lee Jackson | Jul 27, 2016 at 8:20 AM EDT

JPMorgan Bullish on Biotech: 3 Top Picks to Buy Now

A new JPMorgan research report says it time to buy the health care sector and sell consumer staples, which have…

Chris Lange | May 8, 2016 at 9:45 AM EDT

4 Major FDA Decisions Expected by June

Several big FDA decisions should be coming up in the June quarter for the likes of AstraZeneca and Sarepta Therapeutics.

Chris Lange | May 1, 2016 at 10:50 AM EDT

Analysts Make Major Changes to Top Biotech Ratings

With earnings having just been released for some of the top biotech companies, we saw a flurry of analyst calls…

Lee Jackson | Apr 26, 2016 at 10:05 AM EDT

4 Biotechs That Will Escape Weak Seasonal Trends for the Sector

Typically each year, the first quarter is the slowest for biotech stocks. SunTrust Robinson Humphrey has four stocks rated Buy…

Jon C. Ogg | Apr 20, 2016 at 11:05 AM EDT

Can BioMarin Make Treating Hemophilia More Affordable?

BioMarin Pharmaceutical is ready to break above the $1 billion revenue barrier in 2016, a feat that marks a major…

Chris Lange | Mar 23, 2016 at 11:15 AM EDT

Jefferies Identifies 5 Top Biotech Stocks for Huge Upside

Jefferies believes most of the significant biotech downside already occurred, though volatility could continue in the near term.

1 … 4 5 6 7 8 … 12

BioMarin : BMRN

All BioMarin Articles

Why Credit Suisse Sees 25% Upside at BioMarin

Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential

RBC Likes Large Cap Biotech Leaders for 2017

Top Analyst Upgrades and Downgrades: AK Steel, Celgene, Darden, Delphi Automotive, Johnson & Johnson, US Steel and More

Top Analyst Upgrades and Downgrades: GoPro, Randgold, Teva Pharma, Time Warner, Waste Management and More

Top Analyst Upgrades and Downgrades: Brocade, Facebook, First Solar, Fitbit, ONEOK Partners, Sunrun and More

Top Health Care Earnings Coming Next Week

3 Biotech Stocks Could Be the Next Big Takeover Targets

Merrill Lynch Says the Time to Put Money Into Biotech Is Now

JPMorgan Bullish on Biotech: 3 Top Picks to Buy Now

4 Major FDA Decisions Expected by June

Analysts Make Major Changes to Top Biotech Ratings

4 Biotechs That Will Escape Weak Seasonal Trends for the Sector

Can BioMarin Make Treating Hemophilia More Affordable?

Jefferies Identifies 5 Top Biotech Stocks for Huge Upside

Financial Decisions People Regret Most After Age 50

The 401(k) Bracket Smoothing Math: Why a 66 Year Old Couple With $1.5 Million Should Convert Exactly $90,000 a Year

After Comparing Every Weekly Pay ETF on the Market, Roundhill’s Lineup Is the Only One Somewhat Delivering

The 401(k) Bracket Smoothing Math: Why a 66 Year Old Couple With $1.5 Million Should Convert Exactly $90,000 a Year

Why $34,000 Is the Social Security Tax Threshold Most Retirees Never See Coming

Financial Decisions People Regret Most After Age 50

The 401(k) Bracket Smoothing Math: Why a 66 Year Old Couple With $1.5 Million Should Convert Exactly $90,000 a Year

BioMarin : BMRN

All BioMarin Articles

Why Credit Suisse Sees 25% Upside at BioMarin

Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential

RBC Likes Large Cap Biotech Leaders for 2017

Top Analyst Upgrades and Downgrades: AK Steel, Celgene, Darden, Delphi Automotive, Johnson & Johnson, US Steel and More

Top Analyst Upgrades and Downgrades: GoPro, Randgold, Teva Pharma, Time Warner, Waste Management and More

Top Analyst Upgrades and Downgrades: Brocade, Facebook, First Solar, Fitbit, ONEOK Partners, Sunrun and More

Top Health Care Earnings Coming Next Week

3 Biotech Stocks Could Be the Next Big Takeover Targets

Merrill Lynch Says the Time to Put Money Into Biotech Is Now

JPMorgan Bullish on Biotech: 3 Top Picks to Buy Now

4 Major FDA Decisions Expected by June

Analysts Make Major Changes to Top Biotech Ratings

4 Biotechs That Will Escape Weak Seasonal Trends for the Sector

Can BioMarin Make Treating Hemophilia More Affordable?

Jefferies Identifies 5 Top Biotech Stocks for Huge Upside

Financial Decisions People Regret Most After Age 50

The 401(k) Bracket Smoothing Math: Why a 66 Year Old Couple With $1.5 Million Should Convert Exactly $90,000 a Year

After Comparing Every Weekly Pay ETF on the Market, Roundhill’s Lineup Is the Only One Somewhat Delivering

Featured Reads

The 401(k) Bracket Smoothing Math: Why a 66 Year Old Couple With $1.5 Million Should Convert Exactly $90,000 a Year

Why $34,000 Is the Social Security Tax Threshold Most Retirees Never See Coming